Barry Byrne

1 month ago | ajmc.com | Barry Byrne |Kyle Munz |Rose McNulty

Barry Byrne, MD, PhD, pediatric cardiologist and director of the Powell Gene Therapy Center at the University of Florida, discusses considerations when administering gene therapies to pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD). This transcript was lightly edited; captions were auto-generated. TranscriptAre there unique considerations that must be taken into account when administering gene therapies to pediatric patients?

1 month ago | ajmc.com | Kyle Munz |Barry Byrne

Adeno-associated virus (AAV)–mediated gene therapy has particularly transformed the treatment landscape of Duchenne muscular dystrophy (DMD); however, clinical approaches with this intervention vary based on a number of factors. Here, Barry Byrne, MD, PhD, pediatric cardiologist, director, Powell Gene Therapy Center, University of Florida, discussed these considerations, the underlying mechanisms of AAV-mediated gene therapy, and its impacts on clinical approaches to DMD.

Sep 24, 2024 | mdpi.com | Barry Byrne |Laurent Servais |Lindsey Lee Lair |Anne Connolly

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.